Fresh Tracks Therapeutics, Inc. (FRTX) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Fresh Tracks Therapeutics, Inc. (FRTX) Healthcare & Pipeline Overview

Fresh Tracks Therapeutics, Inc. is a clinical-stage biotechnology firm developing prescription therapeutics for autoimmune, inflammatory, and debilitating diseases. The company's pipeline features candidates like sofpironium bromide for hyperhidrosis and BBI-02 for autoimmune conditions, leveraging strategic collaborations to advance its drug development efforts in the U.S.

What Is the Investment Thesis for FRTX?

Fresh Tracks Therapeutics, Inc. presents an investment thesis centered on its clinical-stage pipeline and strategic collaborations within the high-potential biotechnology sector, despite its current market capitalization of $5.59M and a negative profit margin of -71.1%. A primary value driver is sofpironium bromide, which has completed Phase III clinical trials for primary axillary hyperhidrosis, offering a potential pathway to market entry and revenue generation. The successful regulatory approval and commercialization of sofpironium bromide would significantly de-risk the company and provide a foundational revenue stream. Further growth catalysts include the progression of BBI-02, an oral DYRK1A inhibitor for autoimmune and inflammatory diseases, and BBI-10, a STING inhibitor for autoinflammatory and rare genetic diseases, through clinical development. Positive clinical trial data for these programs could unlock substantial value by demonstrating efficacy and safety in large and underserved therapeutic markets. The company's strategic license and collaboration agreements with entities like Carna Biosciences and Voronoi Inc. are crucial for leveraging external expertise and resources, potentially accelerating development timelines and mitigating R&D costs. However, the investment carries inherent risks typical of clinical-stage biopharmaceutical companies, including the high probability of clinical trial failures, regulatory hurdles, and intense competition. The company's small size (4 employees) and reliance on external partnerships also present operational risks. The current gross margin of 100.0% indicates that the company is not yet generating significant product revenue, relying on licensing or development milestones. Future success hinges on successful clinical outcomes, regulatory approvals, and effective commercialization strategies for its pipeline assets.

Based on FMP financials and quantitative analysis

FRTX Key Highlights

• Market Capitalization: $0.01 billion, reflecting its status as a clinical-stage biotechnology company.
• Profit Margin: -71.1%, indicative of significant R&D expenditures typical for companies in the drug development phase prior to commercialization.
• Gross Margin: 100.0%, suggesting that current revenue, if any, is not derived from product sales requiring a cost of goods sold, but rather from licensing or collaboration agreements.
• Beta: 1.17, indicating slightly higher volatility compared to the broader market, common for biotechnology stocks.
• Pipeline Progress: Sofpironium bromide has completed Phase III clinical trials, representing the most advanced asset in the company's development portfolio.

Who Are FRTX's Competitors?

FRTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FRTX's Key Strengths?

• Advanced clinical pipeline with sofpironium bromide having completed Phase III trials for primary axillary hyperhidrosis.
• Diverse pipeline targeting multiple high-value therapeutic areas: autoimmune, inflammatory, autoinflammatory, and rare genetic diseases.
• Strategic license and collaboration agreements providing access to external expertise and resources.
• Focus on novel mechanisms of action (e.g., DYRK1A and STING inhibitors) for differentiated therapies.

What Are FRTX's Weaknesses?

• Clinical-stage company with no currently commercialized products and negative profit margins (-71.1%).
• Small operational team of 4 employees, indicating high reliance on external partners and potential resource constraints.
• High cash burn rates typical of biotechnology R&D, requiring ongoing financing.
• Significant regulatory and clinical development risks inherent in the pharmaceutical industry.

What Could Drive FRTX Stock Higher?

• Potential regulatory approval and commercial launch of sofpironium bromide for primary axillary hyperhidrosis, following its completed Phase III trials.
• Announcement of clinical trial initiation or data readouts for BBI-02, an oral DYRK1A inhibitor for autoimmune and inflammatory diseases.
• Progression of BBI-10, a covalent STING inhibitor, into later-stage clinical development for autoinflammatory and rare genetic diseases.
• Execution and expansion of strategic license and collaboration agreements to advance pipeline assets and secure additional funding.
• Research and development efforts for next-generation kinase inhibitors, potentially leading to new preclinical or clinical candidates.

What Are the Key Risks for FRTX?

• Financial-distress signal — its Altman Z-Score of -18.68 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-66.5%) — the business is not currently generating profit on shareholder capital.
• Clinical trial failures or unexpected adverse events for any of its pipeline candidates, including sofpironium bromide, BBI-02, and BBI-10.
• Significant capital requirements and reliance on external financing to fund extensive research and development activities, leading to potential shareholder dilution.
• Intense competition from larger pharmaceutical companies and other biotechnology firms developing similar or superior treatments for autoimmune, inflammatory, and rare diseases.
• Regulatory hurdles and potential delays in obtaining marketing approvals for drug candidates, even after successful clinical trials.
• Dependence on third-party collaborators for drug development, manufacturing, and potential commercialization, introducing operational risks outside direct control.

What Are the Growth Opportunities for FRTX?

• Growth opportunity 1: Commercialization of Sofpironium Bromide for Primary Axillary Hyperhidrosis. Sofpironium bromide has completed Phase III clinical trials, positioning it as the company's most advanced asset. The market for hyperhidrosis treatments is substantial, with millions affected globally. Successful regulatory approval and subsequent launch in the United States could provide Fresh Tracks Therapeutics with its first significant revenue stream. This opportunity is relatively near-term, contingent on regulatory review timelines, and could establish the company's commercial capabilities. The market for topical hyperhidrosis treatments is expected to grow, driven by increased awareness and demand for effective, non-invasive solutions, potentially reaching hundreds of millions of dollars annually.
• Growth opportunity 2: Advancement of BBI-02 for Autoimmune and Inflammatory Diseases. BBI-02, an oral DYRK1A inhibitor, targets a broad range of autoimmune and inflammatory conditions. This therapeutic area represents a multi-billion dollar market, with significant unmet needs for effective and well-tolerated oral treatments. Successful progression through clinical trials, particularly demonstrating efficacy and a favorable safety profile in Phase II and III studies, could unlock substantial value. The timeline for this opportunity is medium-to-long term, requiring several years of clinical development, but the potential market size and patient population are vast, offering significant upside if successful.
• Growth opportunity 3: Development of BBI-10 for Autoinflammatory and Rare Genetic Diseases. BBI-10, a covalent STING inhibitor, targets autoinflammatory and rare genetic diseases. While individual rare disease markets are smaller, the collective rare disease market is growing rapidly and commands premium pricing due to high unmet needs and limited treatment options. Successful clinical development and regulatory approval for even a single indication within this category could generate meaningful revenue. This opportunity is long-term, given the early stage of development, but offers the potential for significant impact in specific, high-value therapeutic niches.
• Growth opportunity 4: Expansion of Pipeline through Next-Generation Kinase Inhibitors. Fresh Tracks Therapeutics is also developing next-generation kinase inhibitors. Kinase inhibitors are a proven class of drugs with applications across oncology, immunology, and other therapeutic areas. Identifying and advancing novel, highly selective kinase inhibitors could lead to new drug candidates with differentiated profiles and improved safety/efficacy. This represents a long-term, platform-based growth opportunity, allowing the company to continually replenish its pipeline and target new disease areas within the multi-billion dollar kinase inhibitor market. Success here would demonstrate the company's ongoing R&D innovation capabilities.
• Growth opportunity 5: Leveraging Strategic License and Collaboration Agreements. The company's existing partnerships with Carna Biosciences, Voronoi Inc., Bodor Laboratories, and AnGes, Inc. provide critical access to intellectual property, research capabilities, and potential milestone payments or royalties. Expanding these collaborations or forming new ones could accelerate drug development, share R&D costs, and broaden the company's therapeutic reach without significantly increasing its internal headcount or capital expenditure. These agreements can also validate the scientific merit of Fresh Tracks' programs and attract further investment, representing an ongoing growth mechanism for pipeline expansion and financial flexibility.

What Opportunities Does FRTX Have?

• Successful regulatory approval and commercial launch of sofpironium bromide, establishing a revenue stream.
• Positive clinical trial outcomes for BBI-02 and BBI-10, unlocking access to large autoimmune/inflammatory and rare disease markets.
• Expansion of collaboration agreements to accelerate pipeline development and share financial burden.
• Development of next-generation kinase inhibitors to address new therapeutic targets and expand intellectual property.

What Threats Does FRTX Face?

• Clinical trial failures or unexpected safety issues for any of its pipeline candidates.
• Intense competition from larger pharmaceutical companies and other biotech firms with similar or superior compounds.
• Regulatory delays or failure to obtain marketing approvals.
• Patent expirations or challenges to intellectual property.
• Need for additional capital raises, potentially leading to shareholder dilution.

What Are FRTX's Competitive Advantages?

• Intellectual Property: Patents protecting its drug candidates (sofpironium bromide, BBI-02, BBI-10, and next-generation kinase inhibitors) provide market exclusivity upon approval.
• Clinical Data & Regulatory Approvals: Successful completion of Phase III trials for sofpironium bromide represents a significant hurdle overcome, creating a barrier to entry for competitors.
• Specialized Expertise: Focus on specific biological pathways (e.g., DYRK1A, STING inhibition) and disease areas requires deep scientific knowledge and R&D capabilities.
• Strategic Collaborations: Partnerships with Carna Biosciences, Voronoi Inc., and others provide access to proprietary technologies and shared development resources, enhancing R&D efficiency.

What Does FRTX Do?

Founded in 2009 and headquartered in Boulder, Colorado, Fresh Tracks Therapeutics, Inc. (formerly Brickell Biotech, Inc. until September 2022) operates as a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative prescription therapeutics. The company's strategic focus is on addressing significant unmet medical needs within the autoimmune, inflammatory, and other debilitating disease landscapes across the United States. Fresh Tracks Therapeutics has meticulously built a pipeline of drug candidates, each targeting specific conditions with the potential for substantial therapeutic impact. A cornerstone of its development efforts is sofpironium bromide, a compound that has successfully completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis, a chronic condition characterized by excessive underarm sweating. This advanced-stage asset represents a potential near-term commercial opportunity, pending regulatory approvals. Beyond dermatological conditions, the company is actively advancing BBI-02, an oral DYRK1A inhibitor, which is being developed for the treatment of a range of autoimmune and inflammatory diseases. This program underscores Fresh Tracks Therapeutics' commitment to exploring novel mechanisms of action to address complex immunological disorders. Further diversifying its pipeline, Fresh Tracks Therapeutics is also developing BBI-10, a covalent stimulator of interferon genes (STING) inhibitor. This candidate holds promise for the potential treatment of autoinflammatory and rare genetic diseases, representing an innovative approach to modulate innate immune responses. Additionally, the company is engaged in the research and development of next-generation kinase inhibitors, indicating a broader strategy to leverage advanced pharmacological principles across its therapeutic areas. To bolster its research and development capabilities and accelerate pipeline progression, Fresh Tracks Therapeutics has established a network of strategic license and collaboration agreements. These partnerships include collaborations with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. These alliances provide access to specialized expertise, proprietary technologies, and potentially additional funding, positioning Fresh Tracks Therapeutics to navigate the complex drug development process effectively and expand its therapeutic reach within the competitive biotechnology sector. The company's lean operational structure, with only 4 employees, emphasizes its reliance on strategic partnerships and outsourced development models.

What Products and Services Does FRTX Offer?

• Develops prescription therapeutics for autoimmune diseases.
• Focuses on inflammatory and other debilitating diseases in the United States.
• Advances sofpironium bromide, which completed Phase III trials for primary axillary hyperhidrosis.
• Researches BBI-02, an oral DYRK1A inhibitor for autoimmune and inflammatory conditions.
• Develops BBI-10, a covalent STING inhibitor for autoinflammatory and rare genetic diseases.
• Engages in the discovery of next-generation kinase inhibitors.
• Maintains license and collaboration agreements with various biotech partners like Carna Biosciences and Voronoi Inc.
• Operates as a clinical-stage pharmaceutical company, meaning its products are in development, not yet widely commercialized.

How Does FRTX Make Money?

• Primarily generates value through the research, development, and clinical advancement of novel drug candidates.
• Aims to commercialize approved therapeutics, generating revenue from product sales (e.g., if sofpironium bromide is approved).
• Leverages license and collaboration agreements to access technologies, share development costs, and potentially receive milestone payments or royalties.
• Focuses on developing intellectual property around its drug candidates to secure market exclusivity upon approval.

What Industry Does FRTX Operate In?

Fresh Tracks Therapeutics operates within the highly dynamic and research-intensive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles, but also offers substantial rewards for successful drug innovation. Key market trends include a growing focus on precision medicine, targeted therapies for autoimmune and inflammatory diseases, and the development of novel mechanisms of action for rare genetic conditions. Fresh Tracks Therapeutics positions itself as a clinical-stage innovator, focusing on novel small molecule therapeutics. Its competitive landscape includes numerous established pharmaceutical giants and a multitude of smaller, specialized biotech firms, all vying for market share in specific therapeutic areas. The company differentiates itself through its specific drug candidates, such as the DYRK1A inhibitor BBI-02 and the STING inhibitor BBI-10, which target distinct biological pathways, and its advanced-stage sofpironium bromide, which addresses a specific dermatological condition. Success in this industry is heavily dependent on clinical trial outcomes, intellectual property protection, and strategic partnerships.

Who Are FRTX's Key Customers?

• Ultimately, patients suffering from autoimmune, inflammatory, primary axillary hyperhidrosis, autoinflammatory, and rare genetic diseases.
• Healthcare providers (physicians, specialists) who prescribe the company's approved therapeutics.
• Pharmaceutical distributors and pharmacies involved in the supply chain of prescription drugs.
• Potential pharmaceutical partners for licensing or co-development opportunities.

Company Profile

Fresh Tracks Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boulder, US. The company is led by CEO Albert Nicholas Marchio II. FRTX has traded publicly since 1993.

How Fresh Tracks Therapeutics, Inc. Is Valued

Fresh Tracks Therapeutics, Inc. carries a market capitalization of $5.59M, placing it in the micro-cap category. Relative to its peer group, FRTX's quantitative score of 54/100 is below the peer average of 73/100.

ROE -67%Key Financial Metrics

Return on equity for Fresh Tracks Therapeutics, Inc. stands at -66.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -49.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -77.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.98 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -103.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Fresh Tracks Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -18.68 places it in the distress zone, a signal of elevated financial risk.

FRTX Financials

FRTX Latest News

No recent news available for FRTX.

FRTX Analyst Consensus

FRTX MoonshotScore

Common Questions About FRTX (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources